ose2101
Vaccineexperimental
Clinical trial activity
4 trials · 8 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
4
Phase 3
2
Phase 4
0
Earliest trial started Feb 1, 2016 (NCT02654587)
Timeline
Indications
Mechanism of action
- Tumor antigensImmunity, active
Tumor antigens immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- ose2101
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06472245 | Phase 3 | Jun 30, 2024 | Exystat, OSE Immunotherapeutics |
| NCT04713514 | Phase 2 | Aug 5, 2021 | ARCAGY-GINECO, Institut Gustave Roussy, Merck, OSE Immunotherapeutics |
| NCT03806309 | Phase 2 | Feb 7, 2019 | Curie Institute, Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR), OSE Immunotherapeutics |
| NCT02654587 | Phase 3 | Feb 1, 2016 | Orion Corporation, OSE Immunotherapeutics |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (8)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| OSE Immunotherapeutics | For profit | 4 | 2 | 2 | 2016 |
| ARCAGY-GINECO | For profit | 1 | 1 | 1 | 2021 |
| Curie Institute | Academic/Hospital | 1 | 0 | 1 | 2019 |
| Exystat | For profit | 1 | 0 | 1 | 2024 |
| Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR) | Academic/Hospital | 1 | 1 | 1 | 2019 |
| Institut Gustave Roussy | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Merck | For profit | 1 | 0 | 1 | 2021 |
| Orion Corporation | For profit | 1 | 0 | 1 | 2016 |
8 organizations
Page 1 / 1